Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OmniAb Inc. (OABIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: OABIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.56% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.65 | 52 Weeks Range 0.16 - 0.63 | Updated Date 05/17/2025 |
52 Weeks Range 0.16 - 0.63 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -229.11% | Operating Margin (TTM) -453.64% |
Management Effectiveness
Return on Assets (TTM) -13.18% | Return on Equity (TTM) -21.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 92829276 |
Shares Outstanding - | Shares Floating 92829276 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc. was founded to revolutionize antibody discovery. It has grown through acquisitions and strategic partnerships, aiming to provide a comprehensive platform for therapeutic antibody development.
Core Business Areas
- Antibody Discovery: Provides access to diverse antibody repertoires through transgenic animals and in vitro technologies for therapeutic antibody discovery.
- Antibody Engineering: Offers services to optimize and humanize antibodies for improved efficacy and developability.
- Therapeutic Programs: Develops its own pipeline of therapeutic antibody candidates in various disease areas.
Leadership and Structure
The leadership team consists of experienced executives in biotechnology and pharmaceuticals. The organizational structure includes research and development, business development, and commercial operations.
Top Products and Market Share
Key Offerings
- OmniAb Platform: A suite of transgenic animals used for antibody discovery. Market share is difficult to specify exactly but OmniAb is considered one of the leading platforms. Competitors include Harbour BioMed (HBM), Ligand Pharmaceuticals (LGND), and Ablexis.
- In Vitro Antibody Discovery Services: Services that enable the generation and optimization of antibodies using technologies like phage display. Market share is not publicly available. Competitors include Adimab, Distributed Bio, and LakePharma.
Market Dynamics
Industry Overview
The antibody therapeutics market is experiencing rapid growth, driven by advancements in technology and increasing demand for targeted therapies. Biopharmaceutical companies are actively seeking innovative antibody discovery platforms.
Positioning
OmniAb positions itself as a leading provider of antibody discovery technologies, offering a diverse platform and comprehensive services. Its competitive advantage lies in the breadth of its technology and the expertise of its team.
Total Addressable Market (TAM)
The antibody therapeutics market is expected to reach hundreds of billions of dollars. OmniAb is positioned to capture a significant share of this TAM through its various antibody discovery technologies and services.
Upturn SWOT Analysis
Strengths
- Diverse antibody discovery platform
- Experienced leadership team
- Strong intellectual property portfolio
- Established partnerships with pharmaceutical companies
Weaknesses
- Reliance on partnerships for revenue generation
- Limited number of therapeutic programs in clinical development
- Smaller size compared to some competitors
- Stock Price Volatility
Opportunities
- Expansion into new therapeutic areas
- Increased adoption of antibody therapeutics
- Strategic acquisitions to expand technology portfolio
- Development of novel antibody formats
Threats
- Competition from established antibody discovery platforms
- Technological advancements that could render current platforms obsolete
- Regulatory hurdles for therapeutic antibody development
- Economic downturn affecting pharmaceutical R&D spending
Competitors and Market Share
Key Competitors
- HBM
- LGND
- ADYX
Competitive Landscape
OmniAb's advantages include its diverse platform and established partnerships. Disadvantages include smaller size and reliance on partnerships.
Major Acquisitions
Ligand OmniAb Acquisition
- Year: 2022
- Acquisition Price (USD millions): 178
- Strategic Rationale: To acquire the OmniAb platform and expand Ligand's antibody discovery capabilities.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by adoption of OmniAb platform in Pharma as well as services offered.
Future Projections: Future growth is projected based on increasing adoption of their services, new strategic partnerships and therapeutic programs.
Recent Initiatives: Focus on developing and expanding their partnerships and expansion of offerings.
Summary
OmniAb is a leading provider of antibody discovery technologies with a diverse platform and established partnerships. It faces competition from larger companies and relies on partnerships for revenue. The company is focused on expanding its technology portfolio and developing its own therapeutic programs. Future success depends on successful execution of partnerships, successful drug programs and growth in antibody discovery services. Financial performance needs to be better understood to be able to fully assess the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Reports
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated. Financial figures can vary. Stock performance figures are from past data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2021-09-30 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.